Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

REVERSE MERGER (Details Narrative) - USD ($)		6 Months Ended
REVERSE MERGER (Details Narrative) - USD ($)	Jan. 04, 2019	Mar. 31, 2019	Mar. 31, 2018
Number of shares issued		463,636
Shares issued price per share (in dollars per share)		$ 1.10
Proceeds from issuance of stock		$ 1,811,800	$ 2,100,000
Agreement And Plan Of Merger [Member]
Percentage of securityholders collectively own on a fully diluted basis	5.90%
Termination right term	Upon certain terminations of the Merger Agreement, MYnd may be required to pay Emmaus a termination fee of $750,000 and Emmaus may be required to pay MYnd a termination fee of $750,000; provided that if the termination results from the failure to obtain the approval of the continued listing of the post-merger company’s common stock on the NasdaqCM, this fee payable by Emmaus will be $1,600,000.
Third party expenses pay to other party	$ 600,000
Agreement And Plan Of Merger [Member] \| Emmaus Life Sciences, Inc. [Member]
Percentage of securityholders collectively own on a fully diluted basis	94.10%
Percentage of share issued with debt conversion	5.90%